CFO
VRTX icon

CVA Family Office’s Vertex Pharmaceuticals VRTX Stock Holding History

CVA Family Office’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$211K Buy
472
+79
+20% +$36.8K 0.02% 315
2025
Q4 		$178K Buy
393
+5
+1% +$2.15K 0.02% 309
2025
Q3 		$152K Buy
388
+6
+2% +$2.51K 0.02% 339
2025
Q2 		$170K Sell
382
-45
-11% -$20.7K 0.02% 317
2025
Q1 		$207K Buy
427
+44
+11% +$20.5K 0.03% 273
2024
Q4 		$154K Buy
383
+35
+10% +$16.2K 0.02% 310
2024
Q3 		$162K Buy
348
+9
+3% +$4.32K 0.03% 296
2024
Q2 		$159K Buy
339
+13
+4% +$5.64K 0.03% 279
2024
Q1 		$136K Buy
326
+1
+0.3% +$423 0.02% 304
2023
Q4 		$132K Buy
+325
New +$120K 0.03% 296
2023
Q3 		– Sell
-300
Closed -$106K – 932
2023
Q2 		$106K Buy
300
+5
+2% +$1.69K 0.02% 304
2023
Q1 		$92.9K Sell
295
-100
-25% -$30K 0.02% 322
2022
Q4 		$114K Buy
395
+120
+44% +$36.6K 0.03% 273
2022
Q3 		$80K Buy
275
+40
+17% +$11.5K 0.02% 273
2022
Q2 		$66K Hold
235
– – 0.02% 310
2022
Q1 		$61K Buy
235
+135
+135% +$32K 0.01% 361
2021
Q4 		$22K Buy
+100
New +$19.4K 0.01% 513
2021
Q3 		– Sell
-91
Closed -$18K – 877
2021
Q2 		$18K Sell
91
-64
-41% -$13.4K 0.01% 556
2021
Q1 		$33K Buy
+155
New +$34K 0.01% 328

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

CVA Family Office's VRTX Position: Q1 2026 in Review

CVA Family Office increased its Vertex Pharmaceuticals (VRTX) stake by 20% in Q1 2026, buying an estimated $36.8K and bringing the position to 472 shares worth $211K. The position accounts for 0.02% of the portfolio, ranked #315.

CVA Family Office first reported a position in VRTX in Q1 2021 and has held it in 19 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • CVA Family Office held 472 shares of Vertex Pharmaceuticals worth $211K as of Q1 2026.
  • CVA Family Office bought 79 Vertex Pharmaceuticals shares in Q1 2026, an estimated $36.8K.
  • Vertex Pharmaceuticals made up 0.02% of CVA Family Office's portfolio in Q1 2026, its #315 holding.
  • CVA Family Office first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 19 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on CVA Family Office's 13F filing for Q1 2026, filed 29 Apr 2026.